CN103917514B - 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法 - Google Patents

治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法 Download PDF

Info

Publication number
CN103917514B
CN103917514B CN201280054386.3A CN201280054386A CN103917514B CN 103917514 B CN103917514 B CN 103917514B CN 201280054386 A CN201280054386 A CN 201280054386A CN 103917514 B CN103917514 B CN 103917514B
Authority
CN
China
Prior art keywords
compound
tbl1
catenin
cells
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280054386.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103917514A (zh
Inventor
K·N·巴赫拉
S·霍里根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Cat Pharmaceuticals LLC
Original Assignee
Beta Cat Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Cat Pharmaceuticals LLC filed Critical Beta Cat Pharmaceuticals LLC
Publication of CN103917514A publication Critical patent/CN103917514A/zh
Application granted granted Critical
Publication of CN103917514B publication Critical patent/CN103917514B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280054386.3A 2011-11-06 2012-11-06 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法 Active CN103917514B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556245P 2011-11-06 2011-11-06
US61/556,245 2011-11-06
PCT/US2012/063746 WO2013067547A1 (en) 2011-11-06 2012-11-06 METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA

Publications (2)

Publication Number Publication Date
CN103917514A CN103917514A (zh) 2014-07-09
CN103917514B true CN103917514B (zh) 2016-11-16

Family

ID=48192926

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280054386.3A Active CN103917514B (zh) 2011-11-06 2012-11-06 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法

Country Status (15)

Country Link
US (1) US9238030B2 (https=)
EP (1) EP2773607B1 (https=)
JP (1) JP6063472B2 (https=)
KR (1) KR102336767B1 (https=)
CN (1) CN103917514B (https=)
AU (1) AU2012332111B2 (https=)
BR (1) BR112014010584A2 (https=)
CA (1) CA2853491C (https=)
EA (1) EA027770B1 (https=)
ES (1) ES2624427T3 (https=)
IL (1) IL232452A (https=)
MX (1) MX354653B (https=)
SG (1) SG11201402056XA (https=)
WO (1) WO2013067547A1 (https=)
ZA (1) ZA201403003B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963475B2 (en) * 2015-07-28 2018-05-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
TW201718495A (zh) * 2015-07-28 2017-06-01 貝塔貓製藥股份有限公司 蒽-9, 10-二酮二肟化合物前驅藥及其用途
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
WO2019229001A1 (en) * 2018-05-30 2019-12-05 Otto-Von-Guericke-Universität Magdeburg Compounds for the treatment of jak2-v617f-associated cmn
CN119215047A (zh) * 2024-10-11 2024-12-31 浙江大学 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147713A1 (en) * 2007-05-24 2008-12-04 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
CN101730531A (zh) * 2007-05-10 2010-06-09 阿瓦隆药品公司 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途
US20110034441A1 (en) * 2009-08-10 2011-02-10 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
WO2011025685A1 (en) * 2009-08-24 2011-03-03 Merck Sharp & Dohme Corp. Jak inhibition blocks rna interference associated toxicities
WO2011038467A1 (en) * 2009-10-01 2011-04-07 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030302B1 (ru) * 2008-11-21 2018-07-31 Форест Лэборетериз Холдингз Лимитед Антрахинондиоксимы и их применение

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730531A (zh) * 2007-05-10 2010-06-09 阿瓦隆药品公司 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途
WO2008147713A1 (en) * 2007-05-24 2008-12-04 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
US20110034441A1 (en) * 2009-08-10 2011-02-10 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
WO2011025685A1 (en) * 2009-08-24 2011-03-03 Merck Sharp & Dohme Corp. Jak inhibition blocks rna interference associated toxicities
WO2011038467A1 (en) * 2009-10-01 2011-04-07 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BC2059 An inhibitor of the WNT/Beta Catenin Pathway Financing Executive Summary Non-Confidential;β Cat Pharmaceuticals LLC;《 BC2059 Financing Memorandum》;20101112;第1-8页 *
new insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure;N. Thielen，et al;《The Netherlands Journal of Medicine》;20111031;第69卷(第10期);第430-440页 *

Also Published As

Publication number Publication date
ZA201403003B (en) 2017-08-30
KR20140089418A (ko) 2014-07-14
NZ624446A (en) 2016-01-29
JP2014534229A (ja) 2014-12-18
EA201490937A1 (ru) 2014-08-29
EA027770B1 (ru) 2017-08-31
CA2853491C (en) 2019-12-10
KR102336767B9 (ko) 2025-01-08
BR112014010584A2 (pt) 2017-05-02
JP6063472B2 (ja) 2017-01-18
US20130143920A1 (en) 2013-06-06
AU2012332111B2 (en) 2016-11-17
CN103917514A (zh) 2014-07-09
MX354653B (es) 2018-03-07
KR102336767B1 (ko) 2021-12-10
IL232452A (en) 2017-01-31
IL232452A0 (en) 2014-06-30
ES2624427T3 (es) 2017-07-14
EP2773607A1 (en) 2014-09-10
WO2013067547A1 (en) 2013-05-10
EP2773607B1 (en) 2017-03-29
AU2012332111A1 (en) 2014-05-22
SG11201402056XA (en) 2014-10-30
HK1198440A1 (en) 2015-04-24
CA2853491A1 (en) 2013-05-10
US9238030B2 (en) 2016-01-19
EP2773607A4 (en) 2015-03-11
MX2014005498A (es) 2016-05-05

Similar Documents

Publication Publication Date Title
Granja et al. Glucose addiction in cancer therapy: advances and drawbacks
CN103917514B (zh) 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法
US10583129B2 (en) Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
JP2021512105A (ja) 消化管間質腫瘍の治療のための併用療法
HK1251162A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
US9795595B2 (en) Methods for treating cancer
TWI399206B (zh) 抗腫瘤劑
CN112912075B (zh) 治疗前列腺癌的组合疗法
WO2022062223A1 (zh) 金诺芬在制备用于治疗去势抵抗性前列腺癌药物中的应用
JP2013504550A (ja) 癌細胞アポトーシス
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
WO2018232252A1 (en) Methods to treat gliomas using a stat3 inhibitor
WO2015009879A1 (en) Compositions for modulating nrf2-are activity and their methods of use
HK1198440B (en) Treatment of diseases and disorders related to transducin beta-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
US20160095859A1 (en) Combination therapies for overcoming resistance to mitotic agents during chemotherapy
NZ624446B2 (en) Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
HK1253277B (zh) Ep4受体拮抗剂用於治疗nash相关肝癌的用途
HK1229695A1 (en) Novel methods for treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant